Onglyza & Kombiglyze XR Background
Onglyza and Kombiglyze, treatments used for diabetes, are under investigation for a class action lawsuit.
Kombiglyze XR, a prescription drug, is used for the treatment of Type-2 Diabetes. It contains both metformin hydrochloride and saxagliptin. Similarly, Onglyza also has saxagliptin.
Both medicines are prescribed for adults with type 2 diabetes to manage their hyperglycemia (high blood sugar). These drugs are meant to be recommended together with diet and exercise.
In July 2009, the Food and Drug Administration (FDA) had approved Onglyza. Meanwhile, Kombiglyze XR was approved the following year in November 2010.
Both drugs fall under a class of medicines called incretin mimetics. This class of medication is relatively new and has only recently gained attention.
They are used to quicken insulin creation in the pancreas, thus helping to control patients’ blood sugar levels.
Incretin mimetics came into the spotlight when doctors and pharmaceutical companies looked for safer alternatives to treat type-2 diabetes patients.
However, experts soon became wary after Avandia, a popular drug used to treat diabetes before incretin mimetics, got recalled for being connected to cardiac deaths and other dangerous heart side effects.
Onglyza and Kombiglyze Risks
Multinational pharmaceutical companies AstraZeneca and Bristol-Myers Squibb supported a study regarding saxagliptin.
The SAVOR study analyzed 16,492 patients with type-2 diabetes. The study’s goal was to help physicians decide what drug to prescribe their patients for diabetes medications. The study was published in 2013 in the New England Journal of Medicine.
According to the study, patients who ingested saxagliptin have a higher chance of being hospitalized due to heart failure. Saxagliptin can be found in both Onglyza and Kombiglyza XR.
The study’s result alerted experts on the potential risk of using Onglyza and Kombliglyze to treat patients.
The FDA advisory committee mandated AstraZeneca and Bristol-Myers Squibb to include the risk of heart failure in the medicine’s label in April 2015.
Saxagliptin, a prescription drug, is being investigated after reports of patients having severe side effects from taking the medication.
This drug is included in treatments used by Onglyza and Kombiglyze XR for diabetes. Reports of alleged significant and deadly side effects are related to the heart.
According to a recent study, patients who have taken the said diabetes medications are also prone to be hospitalized because of heart failure.
Lawyers of Onglyza and Kombiglyza are looking into the likelihood of taking legal action against the said drug manufacturers.
They aim to represent patients who have suffered damages after consuming the said drugs, including cardiac failure, heart failure, congestive heart failure, or death.
The lawsuit seeks to represent individuals who have been affected or who have lost family members in the last five years because of side effects obtained from Onglyza or Kombiglyze.
Affected individuals can be compensated for damages incurred to them if they join the Onglyza or Kombiglyze XR lawsuits.
The lawsuit investigation covers individuals residing in the following states:
- New Mexico
- New York
- North Carolina
- South Carolina
Editor’s Note on Onglyza and Kombiglyze Being Investigated For A Class Action Lawsuit:
This article is published to inform you of the latest class action lawsuit investigation against Onglyza and Kombiglyze for alleged patient deaths due to heart failure.
What are your thoughts on this piece? Do you know someone who was prescribed Onglyza and Kombiglyze for diabetes treatment?
Please send us a message by clicking the ‘Contact Us’ button below. We’d love to hear back from you!
You might be interested in reading about Natural Cures & Alternative Medicines.